A comprehensive look at the most significant scientific and regulatory shifts of 2023–2025

A Paradigm in Motion

For more than two decades, menopause was defined in clinical practice primarily by what it was not: the end of reproductive function. Treatments were reactive, symptom-focused, and – following the 2002 Women’s Health Initiative (WHI) study – substantially curtailed by regulatory fear. Women were undertreated, underinformed, and frequently told that their symptoms were a normal part of aging, not a medical condition requiring intervention.

That is now changing rapidly. A convergence of new neuroscience, revised pharmacology, a landmark regulatory shift, and a fundamental reconceptualisation of menopause as a whole-body neurobiological transition – not merely a gynaecological event – is reshaping what clinicians know, what treatments are available, and what women can reasonably expect from their healthcare.

This article maps the most important new concepts, one by one.

1. Menopause Is a Brain Event First

Perhaps the most consequential reframing of the past decade comes from neuroscience. The work of Dr. Lisa Mosconi at Weill Cornell Medicine, and a growing body of neuroimaging research, has established that menopause is not primarily an ovarian event – it is a neurological one. The brain is not a passive observer of the hormonal transition; it is its principal stage.

Estrogen receptors, instead of disappearing swiftly after menopause, remain abundant in the brain up to a decade after menopause. Elevated estrogen receptor density was observed during perimenopause – findings that hint that the “window of opportunity” for estrogen therapy may be greater than previously thought.

Research shows that the brain is going through its most profound changes precisely during perimenopause – the warm-up act to menopause in which periods become irregular and symptoms such as hot flashes first appear.

This has enormous clinical implications. Brain fog, memory lapses, mood instability, depression, and anxiety – symptoms that were historically dismissed as psychological, or attributed to poor sleep – are now understood as direct neurological consequences of estrogen withdrawal from the brain. They are not character flaws. They are not stress. They are neurobiological events requiring clinical acknowledgement.

Using a perimenopausal mouse model that mimics the irregular hormone fluctuations of the menopause transition, researchers demonstrated that even partial ovarian hormone decline can lead to increased amyloid deposition and glial activation in the hippocampus. These neuropathological changes appeared before any cognitive symptoms emerged – suggesting that brain vulnerability begins earlier than previously assumed, and that prevention strategies may need to begin before menopause is complete.

The implication is striking: perimenopause – not postmenopause – may be the critical window for neuroprotective intervention.

2. The Timing Hypothesis: When You Start Treatment Is as Important as Whether You Start It

One of the most clinically important new concepts in menopause medicine is the timing hypothesis – the evidence-based proposition that the benefits and risks of menopausal hormone therapy (MHT) are profoundly dependent on when treatment begins relative to the onset of menopause.

The “timing hypothesis” posits that the effects of menopausal HRT on atherosclerosis and clinical events are dependent upon when HRT is initiated in relation to age and/or menopause. The timing hypothesis has been supported by randomised controlled atherosclerosis imaging trials, animal studies, as well as randomised controlled clinical event trials and observational studies taken together.

In women who started HRT earlier, there was a reduced risk of coronary heart disease. A reanalysis of the Nurses’ Health Study observed a benefit to starting HRT less than four years after menopause, compared to more than ten years after.

In women younger than 60 years or within 10 years of menopause, MHT was associated with lower cardiovascular risk. The underlying biological mechanism suggests that in women with minimal atherosclerosis, estrogen has beneficial effects on healthy endothelial function, lipid metabolism, and inflammation. In contrast, initiating MHT in older women or those with established atherosclerosis contributes to increased cardiovascular events.

The practical message is clear: starting MHT in the perimenopause or early postmenopause – not years later, when symptoms have become entrenched and the vascular environment has changed – is where the benefit-to-risk ratio is most favourable. Delaying treatment does not reduce risk; it often increases it, while forfeiting protection.

3. The FDA’s Historic Regulatory Shift: Removing the Black Box

In November 2025, the United States Food and Drug Administration made the most significant regulatory change in women’s health in over twenty years. Risk statements related to cardiovascular disease, breast cancer, and probable dementia were removed from the “boxed warning” – the FDA’s most prominent safety-related warning – for menopausal hormone therapy products.

The FDA announced the initiation of the removal of these warnings from all menopausal hormone therapy (MHT) products, including systemic and low-dose vaginal preparations, citing outdated interpretations of early Women’s Health Initiative (WHI) findings that overstated risks. Extended WHI follow-up and contemporary evidence now show that risks are markedly lower when MHT is initiated in women younger than 60 years or within 10 years of menopause.

The previous warnings were based on the 2002 WHI clinical study in older women, whose average age of participants was 63 years. This study’s focus was to investigate whether hormone therapy could prevent chronic diseases in postmenopausal women; it was not a study designed to evaluate whether HRT was safe or effective for managing menopausal symptoms.

The FDA’s hormone therapy updates include removal of the recommendation to prescribe hormone therapy at the lowest effective dose for the shortest duration, and tailored safety information where, instead of applying identical class-based language across all hormone therapy labels, safety data will be revised to reflect risks most relevant to each specific type of hormone therapy product.

This regulatory shift does not mean MHT is without risk – it means that risks are now communicated accurately, individually, and without the weight of warnings derived from a study population that does not represent the women most likely to benefit. For the first time in over two decades, women and their clinicians can have evidence-based conversations about hormone therapy without the shadow of outdated fear.

4. A New Class of Non-Hormonal Treatments: Neurokinin Receptor Antagonists

For women who cannot or choose not to use hormone therapy, a genuinely new treatment paradigm has emerged: the neurokinin receptor antagonists, which address the underlying brain mechanism of hot flushes directly, for the first time in history.

Hot flushes are caused by overactivity of hypothalamic KNDy neurons – a neuronal system that regulates temperature – due to estrogen deficiency. The identification of NKB/neurokinin B receptor (NK3R) signalling as a key mechanism in menopausal hot flashes has driven the development of NK3R antagonists. These antagonists restore the disrupted balance in KNDy neuron activity caused by estrogen deficiency, thereby reducing the frequency and severity of vasomotor symptoms.

Fezolinetant demonstrated nearly a 60% reduction in hot flash frequency across diverse populations. Elinzanetant’s phase 3 OASIS trials showed even greater efficacy, with a 74% reduction in moderate to severe vasomotor symptoms by week 12, along with meaningful improvements in sleep and a low rate of serious adverse events.

The dual-action mechanism of elinzanetant may confer added benefits for mood and sleep, as NK1 receptor modulation affects substance P pathways. These therapies begin working within days – a notable distinction from the gradual onset of hormonal approaches.

A third compound – cendifensine – is currently in phase 2 trials and represents a further evolution, acting through the monoamine system, which allows for improvements in serotonin, norepinephrine, and dopamine signalling alongside KNDy modulation, with potential benefits for mood changes and food cravings that often coincide with hot flashes.

These developments are particularly significant for the estimated 20–25% of menopausal women with breast cancer histories or other contraindications to estrogen – a population that previously had no evidence-based pharmacological option remotely comparable to hormone therapy in efficacy.

5. Perimenopause Is Its Own Clinical Entity – Not Simply a Prelude

One of the most important reconceptualisations in recent literature is the elevation of perimenopause to distinct clinical status. For decades, perimenopause was framed as a waiting room – a transition period to be endured until menopause arrived and treatments could begin in earnest.

The new science rejects this framing entirely. Perimenopause is one of the most significant endocrine transitions in a female’s life. It negatively impacts the female brain and is believed to be a key contributor to a female’s greater lifetime risk for dementia. Two-thirds of all persons with dementia are female, and females have a two-fold greater lifetime risk of developing dementia than males. Perimenopause may therefore be a critical window to implement interventions for the promotion of female brain health.

The hormonal fluctuations of perimenopause are in some respects more biologically turbulent than the stable hypoestrogenism of postmenopause. Erratic estrogen oscillations – rather than simple decline – drive a distinctive and often more chaotic symptom profile: mood instability that resembles premenstrual dysphoric disorder, anxiety that appears without prior history, sleep disruption, and cognitive changes that precede the classic hot flush by years.

Menopause represents a window of opportunity – a moment when women are motivated to change health behaviours and when interventions could have the greatest long-term impact on cardiovascular health, bone density, brain function, and metabolic health. Designing effective, theory-driven behaviour change interventions targeted at this window may yield benefits that extend decades beyond the transition itself.

6. Menopause Is a Metabolic Transition – Not Just a Reproductive One

The final conceptual shift concerns the metabolic dimension of menopause – increasingly recognised as inseparable from its hormonal, neurological, and cardiovascular aspects.

Estrogen loss increases insulin resistance, promotes visceral fat deposition, elevates inflammatory markers, disrupts lipid metabolism, and accelerates arterial ageing. These changes begin in perimenopause, often years before the final menstrual period. They are not simply co-occurring health issues of midlife; they are mechanistically linked to estrogen deficiency.

This means that menopause management is not a subspecialty question for gynaecologists alone. It is a question for cardiologists, endocrinologists, neurologists, and primary care physicians. The woman entering perimenopause is at the beginning of a metabolic transition whose consequences – cardiovascular disease, type 2 diabetes, dementia, osteoporosis – will manifest a decade or more later. The perimenopause window is when preventive intervention is most effective. When you view menopause as a transition rather than a disease, you start asking “how do we support women’s cardiovascular health, cognitive function, bone density, skin integrity, sexual wellness, and quality of life through this passage?” instead of just “how do we suppress hot flashes?”

What This Means for Women Right Now

The collective message of this new science is unambiguous: perimenopause and menopause are not events to be endured quietly, managed minimally, and medicated only when symptoms become unbearable. They are a clinically significant transition with long-term health consequences that are most effectively addressed early, comprehensively, and individually.

The tools now available – refined hormone therapy guidance, the neurokinin receptor antagonists, better understanding of the brain-menopause connection, and a regulatory environment that no longer overstates risk – mean that women have more evidence-based options than at any previous point in history.

What has not yet kept pace is clinical practice. Women still wait an average of several years before receiving appropriate treatment. They are still told their symptoms are normal, inevitable, or psychological. They are still denied conversations about hormone therapy by clinicians operating from 2002 data.

The science has moved. The task now is ensuring that clinical practice – and the women who deserve its benefits – moves with it.

For more useful articles and expert guidance, explore the Womeno app – your personal digital companion through the hormonal transition. Download the app HERE.

Sources

1. Mosconi L et al. Estrogen receptor density changes during the menopausal transition: neuroimaging evidence. Weill Cornell Medicine / National Institute on Aging. 2024. news.weill.cornell.edu
2. Mosconi L. The Menopause Brain. Avery/Penguin Random House. 2024. ISBN: 9780593541241.
3. Marongiu R et al. Amyloid deposition and neuroinflammation in perimenopausal mouse models: neuropathology precedes cognitive symptoms. Frontiers in Aging Neuroscience – Editorial. PMC12635531. 2025.
4. Barha C. SMART Brain: Study of Menopause and Resistance Training on Brain Health. Innovation in Aging. 2025. PMC12762979. doi:10.1093/geroni/igaf122.1802
5. Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease. Cancer Journal. 2022. PMC9178928.
6. Cho L et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. 2023;147(7):597–610. doi:10.1161/CIRCULATIONAHA.122.061559
7. Sood R et al. Menopausal Hormone Therapy and Heart Risk: Updated Guidance. Cleveland Clinic Consult QD. February 2024. consultqd.clevelandclinic.org
8. Iyer P et al. The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: a narrative review. PMC12872825. 2025.
9. Yanachkova V et al. Menopausal Hormone Therapy – Risks, Benefits and Emerging Options: A Narrative Review. PMC12652300. 2025.
10. FDA. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. Official FDA Press Release. February 12, 2026. fda.gov
11. FDA. FDA Requests Labeling Changes for Menopausal Hormone Therapies. November 10, 2025. fda.gov
12. PMC12889233. FDA’s 2025 removal of black box warnings on menopausal hormone therapy. 2025.
13. Dodin S et al. A New Hope for Women with Vasomotor Symptoms: Neurokinin B Antagonists. PMC11900985. 2025.
14. Rahman M et al. Efficacy and safety of fezolinetant for vasomotor symptoms: a systematic review and meta-analysis. Medicine. 2023. PMC10727556.
15. Pinkerton JV. Special Report: How neurokinin receptor antagonists are reshaping the VMS treatment landscape. Contemporary OB/GYN. April 2025. contemporaryobgyn.net
16. Dunsmoor-Su R. New nonhormonal therapies transform hot flash treatment in menopause. Contemporary OB/GYN. January 2026. contemporaryobgyn.net
17. Sassarini J et al. Comparative efficacy of elinzanetant versus other non-hormonal therapies for VMS. AJMC/AMCP 2025 Annual Meeting. April 2025. ajmc.com
18. Hemmings C. Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms. Drugs. 2025. doi:10.1007/s40265-025-02231-8
19. Money A et al. Menopause as a window of opportunity. Proceedings of the Nutrition Society. 2023. doi:10.1017/S0029665123003506